LivaNova Unveils Positive Five-Year Clinical Data for aura6000™ System in Treating Obstructive Sleep Apnea at ISSS 2025 Annual Meeting

Reuters

2025/10/07

LivaNova Unveils Positive Five-Year Clinical Data for aura6000™ System in Treating Obstructive Sleep Apnea at ISSS 2025 Annual Meeting

LivaNova plc has announced its upcoming participation in the International Surgical Sleep Society (ISSS) 2025 Annual Meeting in Indianapolis, where the company will present new scientific data on its aura6000™ System for the treatment of moderate to severe obstructive sleep apnea (OSA). The company will deliver a five-year analysis from the THN-3 randomized controlled trial, as well as 12-month top-line data from the follow-on OSPREY randomized controlled trial. The results, which demonstrate the durability and retention of benefits of proximal hypoglossal nerve stimulation (p-HGNS) therapy, will be shared during oral and poster presentations scheduled for October 9 and 10, 2025. In November 2024, LivaNova announced that the OSPREY trial met its primary and secondary endpoints after six months of therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Livanova plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20251007619591) on October 07, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2573396884"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573396884\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573396884?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-07 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573396884","market":"fut","top_or_hot":-1,"title":"LivaNova Unveils Positive Five-Year Clinical Data for aura6000™ System in Treating Obstructive Sleep Apnea at ISSS 2025 Annual Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      LivaNova Unveils Positive Five-Year Clinical Data for aura6000™ System in Treating Obstructive Sleep Apnea at ISSS 2025 Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        LivaNova plc has announced its upcoming participation in the International Surgical Sleep Society (ISSS) 2025 Annual Meeting in Indianapolis, where the company will present new scientific data on its aura6000™ System for the treatment of moderate to severe obstructive sleep apnea (OSA). The company will deliver a five-year analysis from the THN-3 randomized controlled trial, as well as 12-month top-line data from the follow-on OSPREY randomized controlled trial. The results, which demonstrate the durability and retention of benefits of proximal hypoglossal nerve stimulation (p-HGNS) therapy, will be shared during oral and poster presentations scheduled for October 9 and 10, 2025. In November 2024, LivaNova announced that the OSPREY trial met its primary and secondary endpoints after six months of therapy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Livanova plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20251007619591) on October 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LivaNova Unveils Positive Five-Year Clinical Data for aura6000™ System in Treating Obstructive Sleep Apnea at ISSS 2025 Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLivaNova Unveils Positive Five-Year Clinical Data for aura6000™ System in Treating Obstructive Sleep Apnea at ISSS 2025 Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-07 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      LivaNova Unveils Positive Five-Year Clinical Data for aura6000™ System in Treating Obstructive Sleep Apnea at ISSS 2025 Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        LivaNova plc has announced its upcoming participation in the International Surgical Sleep Society (ISSS) 2025 Annual Meeting in Indianapolis, where the company will present new scientific data on its aura6000™ System for the treatment of moderate to severe obstructive sleep apnea (OSA). The company will deliver a five-year analysis from the THN-3 randomized controlled trial, as well as 12-month top-line data from the follow-on OSPREY randomized controlled trial. The results, which demonstrate the durability and retention of benefits of proximal hypoglossal nerve stimulation (p-HGNS) therapy, will be shared during oral and poster presentations scheduled for October 9 and 10, 2025. In November 2024, LivaNova announced that the OSPREY trial met its primary and secondary endpoints after six months of therapy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Livanova plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20251007619591) on October 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065169927.USD","symbol_name":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nNDLbLhhmg:1","article_id":"2573396884","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573396884","pubTimestamp":1759842056,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"LivaNova Unveils Positive Five-Year Clinical Data for aura6000 System in Treating Obstructive Sleep Apnea at ISSS 2025 Annual Meeting. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Livanova plc published the original content used to generate this news brief via Business Wire  on October 07, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","BK4082":"医疗保健设备","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LIVN":"LivaNova PLC"},"translate_title":"LivaNova公布aura6000积极的五年临床数据™ISSS 2025年年会上治疗阻塞性睡眠呼吸暂停的系统","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LIVN":0.9},"content_text":"LivaNova Unveils Positive Five-Year Clinical Data for aura6000™ System in Treating Obstructive Sleep Apnea at ISSS 2025 Annual Meeting\n    \n\n        LivaNova plc has announced its upcoming participation in the International Surgical Sleep Society (ISSS) 2025 Annual Meeting in Indianapolis, where the company will present new scientific data on its aura6000™ System for the treatment of moderate to severe obstructive sleep apnea (OSA). The company will deliver a five-year analysis from the THN-3 randomized controlled trial, as well as 12-month top-line data from the follow-on OSPREY randomized controlled trial. The results, which demonstrate the durability and retention of benefits of proximal hypoglossal nerve stimulation (p-HGNS) therapy, will be shared during oral and poster presentations scheduled for October 9 and 10, 2025. In November 2024, LivaNova announced that the OSPREY trial met its primary and secondary endpoints after six months of therapy.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Livanova plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20251007619591) on October 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}